Comparison · NCT00391872-f0fb560f
TICAGRELOR vs CLOPIDOGREL: Participants With Coronary Artery Bypass Graft (CABG) Major Fatal/Life-threatening Bleeding
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. TICAGRELOR vs CLOPIDOGREL: Participants With Coronary Artery Bypass Graft (CABG) Major Fatal/Life-threatening Bleeding. Trial comparisons, record NCT00391872-f0fb560f. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00391872-f0fb560f
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.427 | 0.393 | 0.462 | wilson | |
| Risk in group 2 | 0.419 | 0.385 | 0.453 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00835 | -0.0402 | 0.0569 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.02 | 0.909 | 1.14 | log | |
| Odds ratio, group 1 over group 2 | 1.03 | 0.848 | 1.26 | log | |
| Number needed to treat, for one more participant with the outcome on TICAGRELOR than on CLOPIDOGREL | 120 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | TICAGRELOR | Ticagrelor 90 mg twice daily dose (BD) | 329 | 770 | OG000 |
| Group 2 | CLOPIDOGREL | Clopidogrel 75 mg once daily dose (ODD) | 341 | 814 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Participants With Coronary Artery Bypass Graft (CABG) Major Fatal/Life-threatening Bleeding
- Description
Number of participants with a major fatal/life-threatening CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds.
- Time frame
- First dosing up to 12 months
- Population
- Population is all patients who underwent CABG surgery within 7 days of last dose of active study medication.
Source ClinicalTrials.gov
Trial
- Title
- A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome
- NCT number
- NCT00391872
- Phases
- PHASE3
- Conditions
- Acute Coronary Syndrome
- Interventions
- Ticagrelor, Clopidogrel
- Lead sponsor
- AstraZeneca
- Results first posted
- 2012-03-13
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00391872?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00391872-f0fb560f